Entrada Therapeutics (TRDA) Current Assets (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Current Assets of $266.9 million for Q1 2026, down 33.81% year-over-year from $403.2 million in Q1 2025, and down 12.86% quarter-over-quarter from $306.3 million in Q4 2025.
Entrada Therapeutics (TRDA) Current Assets (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $266.9 million for Q1 2026.
- In Q1 2026, Current Assets fell 33.81% year-over-year to $266.9 million; the TTM figure through Mar 2026 stood at $266.9 million (down 33.81% YoY), while the FY2025 annual figure was $306.3 million, down 30.4% from the prior year.
- Current Assets for Q1 2026 stood at $266.9 million, down from $306.3 million in the prior quarter.
- The five-year high for Current Assets was $489.5 million in Q2 2024, with the low at $209.9 million in Q4 2022.
- The 5-year median for Current Assets is $369.8 million (2023), against an average of $355.4 million.
- The sharpest annual moves came in 2022 and 2026: Current Assets soared 90.03% in 2022, then tumbled 33.81% in 2026.
- Entrada Therapeutics' Current Assets stood at $209.9 million in 2022, then surged by 76.19% to $369.8 million in 2023, then increased by 19.0% to $440.0 million in 2024, then plunged by 30.4% to $306.3 million in 2025, then decreased by 12.86% to $266.9 million in 2026.
- Business Quant data shows TRDA's Current Assets at $266.9 million in Q1 2026, $306.3 million in Q4 2025, and $338.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 232.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 232.70 Mn |
| Mar 31, 2026 | 266.87 Mn |
| Dec 31, 2025 | 306.25 Mn |
| Sep 30, 2025 | 338.26 Mn |
| Jun 30, 2025 | 369.15 Mn |
| Mar 31, 2025 | 403.19 Mn |
| Dec 31, 2024 | 440.04 Mn |
| Sep 30, 2024 | 465.34 Mn |
| Jun 30, 2024 | 489.54 Mn |
| Mar 31, 2024 | 414.17 Mn |
| Dec 31, 2023 | 369.77 Mn |
| Sep 30, 2023 | 383.04 Mn |
| Jun 30, 2023 | 390.20 Mn |
| Mar 31, 2023 | 434.14 Mn |
| Dec 31, 2022 | 209.88 Mn |
| Sep 30, 2022 | 234.73 Mn |
| Jun 30, 2022 | 253.90 Mn |
| Mar 31, 2022 | 272.71 Mn |
| Dec 31, 2021 | 298.70 Mn |
| Sep 30, 2021 | 123.53 Mn |